North Carolina – Regional Life Sciences Roundup -October 23th, 2026
Each week, our Regional Roundup delivers the most important and timely life sciences news from around the region. From groundbreaking research to fundraising, new development projects, and who’s hiring — we bring you the top stories that matter most. Stay informed with a curated selection of the latest news, delivered directly to your inbox weekly.
North Carolina companies spent this week shortening distances: between the lab and the clinic, between an idea and the leader who can scale it, and between a trained worker and an open job.
Fortrea spent roughly $45M to bring sample testing in-house, which it says should speed up early-phase studies, and an Aurobindo subsidiary’s $15.25M purchase of a contract chemistry lab gives it a research arm to feed its large-scale manufacturing. Clinical ink’s shared-control recapitalization and CREO’s new CEO show two more firms setting up for their next stage of growth.
The science is chasing shorter paths, too. SAS and NC State are testing whether AI can predict how a treatment will behave in people before it reaches the clinic, and United Therapeutics won FDA clearance for a second try at a lung disease with no approved treatment, this time with a different inhaler.
The people side was the most mixed. UNC Pembroke is offering a free course to move newcomers into biomanufacturing jobs, while Pfizer’s layoffs at two manufacturing sites left workers and local leaders waiting for answers. North Carolina is shortening the path from idea to patient, and this week made clear how much of that path runs through people.
Financial
Tracking the capital moving through North Carolina— funding rounds, M&A activity, and investment trends shaping NC’s life sciences companies.
A Durham CRO Spends $45M to Bring Its Sample Testing In-House
Fortrea has completed its roughly $45 million all-cash purchase of the early phase services division of Worldwide Clinical Trials, adding a clinical pharmacology unit and a bioanalytical laboratory in Texas. Fortrea says bringing the lab in-house will cut handoffs between clinical sites and sample analysis, which should speed up early-phase studies. It’s a deal between two Triangle-area research companies, with Worldwide saying it will keep supporting Phase I work while investing more in late-stage services. Read More >
Clinical ink Secures Strategic Investment From Ardan Equity and GI Partners
Clinical ink, which builds electronic clinical outcome assessment and connected device technology for clinical trials, has received new equity investment from two private equity firms that will now share control. It’s a recapitalization rather than a traditional fundraising round: an existing investor reinvested through a newer fund and brought in a second firm as an equal partner. Financial terms weren’t disclosed, and the company says the new owners will help scale its platform globally across clinical research and clinical care. Read More >
A1 Biochem Labs Joins an Aurobindo Subsidiary in a $15.25M Cash Deal
A contract chemistry lab has been acquired by a subsidiary of a large generic drugmaker in a cash deal worth about $15.25 million. The lab provides custom synthesis, medicinal chemistry, and early-stage process development for drug developers, and the buyer says pairing that front-end research with its large-scale ingredient manufacturing will let clients stay with one partner from lab bench to commercial production. The founder keeps a minority stake and stays on with the group. Read More >
People
Who we’re buzzing about this week — the leadership moves, board appointments, and rising names shaping the region’s life sciences community.
Travis Psencik A Certified Project Leader Steps Into a Key Seat at FUJIFILM Biotechnologies
FUJIFILM Biotechnologies, a global contract development and manufacturing organization (CDMO), has brought on a certified Program Manager to keep complex biologics programs moving from clinical development to commercial scale. The role connects a client’s scientific milestones with the realities of the manufacturing floor, where a missed schedule can delay patient access to new therapies. The hire signals how much CDMOs lean on structured project leadership as demand for biomanufacturing keeps growing. Read More >
A Founder-Led Consultancy Hands Over the Keys: Meet the New CEO, Matthew Klein
CREO, a Durham-based consulting firm that serves the life sciences industry, has named an outside executive as its new CEO while its two co-founders move into senior consulting roles. The change marks a shift from a founder-led boutique to a larger platform, backed by a healthcare-focused private equity firm. The new CEO comes from a global consultancy, where he led the life sciences practice and helped build its commercial and operational side. Read More >
Stephen Brannan and John Young Join Slate Medicines as Board Members
Slate Medicines, a Raleigh-based clinical-stage company developing treatments for migraine, has added two experienced drug-industry leaders to its board as its lead antibody candidate advances. One brings more than 25 years of central nervous system drug development experience, and the other a long career in corporate strategy and commercialization at a global pharmaceutical company. The company says the appointments will strengthen oversight of both clinical progress and preparation for the market. Read More >
Workforce
The hiring activity, team expansions, and talent trends driving growth across North Carolina’s life sciences and biotech employers.
UNCP Offers Free Bioprocessing Training For Entry-Level Biomanufacturing Jobs
UNC Pembroke is offering a free, two-week bioprocessing course that prepares adults for entry-level roles in biopharmaceutical manufacturing. Offered in collaboration with industry employers, the hands-on training leads to several certifications, including an advanced credential in biopharmaceutical manufacturing. Seats are limited, and participants must finish online modules before the in-person session begins. Read More >
Pfizer Announces Layoffs at North Carolina Facilities, Leaving Workers and Local Leaders Seeking Answers
Pfizer has told employees at two of its manufacturing sites that job cuts are coming, but it hasn’t said how many positions are affected, when the reductions will take effect, or which departments are involved. The company says the cuts are part of a broader effort to improve efficiency and that it will provide support services to affected employees. Local leaders say the lack of detail is their main concern, and no state layoff (WARN) notice had been filed as of Wednesday afternoon. Read More >
Who’s hiring?!
Top Employer
KBI Biopharma is a global contract development and manufacturing organization (CDMO) that helps pharma and biotech companies take a drug from early development through clinical and commercial manufacturing. It operates eight locations across the U.S. and Europe and says it serves more than 500 clients, from early-stage biotechs to large pharmaceutical firms.
In North Carolina, KBI has a site in the Durham and Research Triangle Park area, alongside its locations in Colorado, Texas, Switzerland, and Belgium. Its services include process development, cGMP manufacturing, cell line development, and advanced analytical work such as mass spectrometry.
They are currently hiring across 13 roles in the North Carolina region. Apply Now >
Other employers and available roles we’re paying attention to this week:
- Kymanox (Morrisville, NC) is hiring a (Contract) Quality, Veeva Document Admin | Apply Now >
- Novo Nordisk (Durham, NC) is hiring a Senior Environmental, Health & Safety Engineer | Apply Now >
- Chiesi USA (Cary, NC ) is hiring a Global Regulatory Affairs Manager | Apply Now >
- Baxter International Inc. (Raleigh, NC) is hiring a Associate Project Manager | Apply Now >
- Zoll Medical Corporation (Raleigh, NC) is hiring a Territory Manager, Ventilation | Apply Now >
Clinical + Commercial
The latest clinical trial progress, regulatory milestones, and commercial launches from companies advancing science from the lab to the market across North Carolina.
Can a Pill Stop Dangerous Blood Sugar Crashes After Weight-Loss Surgery? A New Trial Launches
Vogenx has launched EMERGE, a Phase 2b trial testing whether an oral drug can reduce dangerous blood sugar crashes in people who have had weight-loss surgery. The condition, called post-bariatric hypoglycemia, has no approved treatment, and the company says its drug works mainly in the gut to slow sugar absorption. The placebo-controlled study aims to build on earlier, smaller studies, though the company has not said whether the first participant has been dosed. Read More >
FDA Clears United Therapeutics for a Second Shot at a Lung Disease With No Approved Treatment
United Therapeutics has received FDA clearance to begin SUMMIT, a Phase 2 trial of an investigational soft mist inhaler form of treprostinil in people with pulmonary hypertension linked to chronic obstructive pulmonary disease (PH-COPD), a condition with no approved treatment. The study will focus first on safety and tolerability, and it follows an earlier attempt in this patient group with a different inhaled form that ended early on the recommendation of an independent safety committee. The company says the new device and a more carefully defined patient group set this effort apart, though it remains early and investigational. Read More >
Two Targets, One Molecule: A Durham Team Bets on a New Kind of RNA Medicine
Brii Biosciences, a Hong Kong-listed biotech with U.S. operations in Durham, has launched BRiSC, an in-house platform for discovering RNA medicines built to silence two disease targets with a single drug. The company says it will start with metabolic disorders, where overlapping biology could benefit from hitting more than one pathway at once. The work is still at the discovery stage, and no drug candidates have been named. Read More >
Ecosystem
The partnerships, programs, and policy moves building North Carolina’s life sciences infrastructure — and the organizations driving it forward.
Strategic Partnership Attempt to Answer How Do Patient Samples Cross Oceans Without Losing Time?
LabConnect, a central laboratory that tests patient samples for clinical trials, has signed a memorandum of understanding with GCCL, a clinical trial sample analysis lab, to coordinate global studies. The agreement formalizes a working relationship the companies say has lasted more than 20 years, and it outlines shared sales leads, joint project management, and combined marketing. Read More >
Backing the Next Generation: Inside Parexel’s Scholarship and New Early-Career Award
Parexel used the 2026 Society for Clinical Research Sites Global Site Solutions Summit to lead discussions on how research sites and clinical research organizations can work together more effectively, from site selection to trial startup. The company also honored emerging research sites through a scholarship program that offers mentorship and professional development, and it planned to present a new award for early-career professionals working at the site level. Parexel says its network of alliance sites helps trials start faster and enroll more patients, a claim based on its own data. Read More >
Can AI Predict How a Treatment Will Behave in People Before the Clinic? SAS and NC State Aim to Find Out
SAS and NC State University have launched a research partnership that brings data and AI expertise into life sciences research, starting with a project on predicting how diseases and potential therapies will behave in people before they reach the clinic. Researchers will test AI methods built for small, information-dense datasets from lab models such as organoids and organ-on-chip devices, which could eventually help scientists spot promising treatments sooner. The two-year pilot is designed to scale up, and neither organization shared financial terms. Read More >
Other [Good] Reads
Editor’s picks from across the web — the stories, videos, and podcasts shaping the conversation in NC biotech and life sciences this week.
Can Gene Therapy Move Beyond Rare Disease and Reach Millions?
Gene therapy has proven its value in a handful of rare diseases, but what would it take to reach conditions like Parkinson’s disease and heart failure that affect millions of people? The next chapter depends on four things: choosing the right biological targets, delivering treatments more precisely, manufacturing at far greater scale, and making sure patients can actually get them. It’s a short, readable look at where the field is heading and why no single organization can get there alone. Read More >
On the Calendar
A few of the upcoming events, conferences, and networking opportunities across North Carolina’s life sciences ecosystem that you don’t want to miss.
BioFuture: The Nexus for Innovators, Investors, and Changemakers to Rethink and Shape the Future of Healthcare
Tuesday-Wednesday, October 27-28, 2026 • Research Triangle Park, NC
Hosted by BioFuture | Register Now >
North Carolina Global Health and AI Conference
Friday, November 6, 2026 • 8:30 AM – 3 PM • Durham, NC
Hosted by North Carolina Global Health Alliance | Register Now >
Triangle BioTech Tuesday
Tuesday, November 10, 2026 • 5:30 PM – 7:30 PM • ReCity Network in Durham, NC
Hosted by Triangle Biotech | Register Now >
Did we miss something!? Drop us a line →
Stay connected to North Carolina’s Region life sciences.
🔍 Explore companies → · 💼 Browse jobs → · 📅 See events → · 📰 Read more →
Get the North Carolina Region Roundup every Friday.
The week’s most important life sciences news from the NC region— delivered to your inbox.
